Key to understanding the basis for a disease is to define its cell of origin and what drives that cell to become pathologic. Further, to understand the LCH cell of origin, one needs to place it in the ...

New research overseen by University of Colorado Cancer Center member Rebecca Schweppe, PhD, could lead to improved treatment for people with thyroid cancer characterized by a mutation in the BRAF gene ...

Anticancer drug resistance remains a crucial impediment to the care of many patients with cancer. Although the exact mechanisms of resistance may differ for each therapy, common mechanisms of ...

Raf kinases are components of the MAP kinase pathway, a signal transduc-tion pathway that normally controls cell growth and division downstream of activated cell surface growth factor receptors. RAF1, ...

Oncotarget Volume 11, Issue 34 features Figure 1, "BRAF inhibitor-induced changes in cell viability," by Pickles, et al. which reported that the BEACON CRC trial demonstrated a survival advantage over ...

Oncotarget Volume 11, Issue 34 features Figure 1, "BRAF inhibitor-induced changes in cell viability," by Pickles, et which reported that the BEACON CRC trial demonstrated a survival advantage over ...

Researchers have discovered a signaling pathway between cytokines and BRAF that promotes tumor growth. The finding could provide a potential therapeutic target. The protein BRAF is a key player in the ...

Cancer genomic profiling is rapidly transforming the clinical management of cancer patients. Results from our study indicate that metastatic colorectal cancer patients with certain BRAF mutations ...

CHICAGO & SHANGHAI--(BUSINESS WIRE)--JS InnoPharm Ltd initiated the JSI-1187 plus dabrafenib combination dose-escalation phase of the Phase 1 study for patients with locally advanced or metastatic ...

Promising preliminary monotherapy data for ERK1/2 inhibitor ERAS-007 and SHP2 inhibitor ERAS-601 in advanced solid tumors, which had favorable safety, tolerability, and efficacy profiles that support ...